Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. ( Lancet Oncology) U.S.

Bristol-Myers Squibb (NYSE:BMY) recently announced an update from the FDA on CAMZYOS®, focusing on simplified treatment ...

Bristol-Myers Squibb (NYSE:BMY) recently announced an update from the FDA on CAMZYOS®, focusing on simplified treatment ...

Cutaneous immune-related adverse events that develop after immune checkpoint inhibitor therapy become chronic in nearly ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap ...

The US Justice Department is suing Maine for allowing transgender athletes to compete in women's sports, Attorney General Pam ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...